124 reports of this reaction
3.5% of all FELBAMATE reports
#3 most reported adverse reaction
CONVULSION is the #3 most commonly reported adverse reaction for FELBAMATE, manufactured by Viatris Specialty LLC. There are 124 FDA adverse event reports linking FELBAMATE to CONVULSION. This represents approximately 3.5% of all 3,510 adverse event reports for this drug.
Patients taking FELBAMATE who experience convulsion should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONVULSION is moderately reported among FELBAMATE users, representing a notable but not dominant share of adverse events.
In addition to convulsion, the following adverse reactions have been reported for FELBAMATE:
The following drugs have also been linked to convulsion in FDA adverse event reports:
CONVULSION has been reported as an adverse event in 124 FDA reports for FELBAMATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONVULSION accounts for approximately 3.5% of all adverse event reports for FELBAMATE, making it one of the most commonly reported side effect.
If you experience convulsion while taking FELBAMATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.